1887
Volume 2025, Issue 1
  • EISSN: 3008-0738

Abstract

The COVID-19 pandemic has had a profound impact on global health, with millions of confirmed cases and deaths. Vaccination is crucial in curbing the spread of the virus and mitigating severe outcomes. However, the swift development and deployment of COVID-19 vaccines have raised concerns about potential adverse events, underscoring the need for comprehensive surveillance and analysis of vaccine safety.

This study aimed to compare the prevalence and types of adverse events reported following the administration of different COVID-19 vaccines (AstraZeneca, Moderna, Pfizer, Pfizer Pediatric) across various doses. The objective was to delineate patterns in both local and systemic symptoms, including severe reactions such as anaphylaxis, to enhance understanding of the safety profiles of these vaccines.

We conducted a retrospective analysis of Electronic Health Records from Qatar’s Primary Health Care Corporation, focusing on individuals aged 6 months and older. Adverse event data were gathered using the “COVID-19 Post Vaccine Assessment Form,” which captures both local and systemic symptoms. Data were analyzed using IBM SPSS Statistics for Windows, Version 29.0, with frequencies and percentages summarized, Chi-square tests applied to assess associations between side effects and vaccine doses, and a p-value < 0.05 (two-tailed) considered statistically significant.

The study included 121,700 patients, of whom 28,715 (23.6%) reported at least one adverse event following vaccination. Moderna exhibited the highest prevalence of any symptoms after the second dose (34.3%), while AstraZeneca demonstrated a significant increase in symptoms after the third dose (96.9%). Injection site pain was most prevalent with AstraZeneca’s third dose (57.1%), and anaphylaxis was most commonly reported with Pfizer Pediatric’s first dose (0.9%). The Pfizer Pediatric vaccine had the lowest rates of symptoms after the third dose (0.5%). Systemic symptoms, including fever and fatigue, were frequently reported across all vaccines.

This study reveals significant variability in adverse event profiles among different COVID-19 vaccines and doses. Moderna and AstraZeneca showed higher rates of both local and systemic symptoms, with AstraZeneca’s third dose exhibiting the highest overall symptom prevalence. Pfizer Pediatric had lower adverse event rates, though anaphylaxis and systemic symptoms like fever were more notable after the first dose. These findings emphasize the importance of ongoing post-vaccination monitoring to optimize vaccine administration and ensure patient safety.

© 2025 The Author(s), Licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qjph.2025.4
2025-05-24
2025-07-16
Loading full text...

Full text loading...

/deliver/fulltext/qjph/2025/1/qjph.2025.4.html?itemId=/content/journals/10.5339/qjph.2025.4&mimeType=html&fmt=ahah

References

  1. World Health Organization. WHO coronavirus disease 2019 (COVID-19) situation report-52.2024 [cited 2020 Nov 29]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4
     [Google Scholar]
  2. Centers for Disease Control and Prevention. CDC Covid Data Tracker.[cited 2023 Oct 10]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
     [Google Scholar]
  3. da Rosa Mesquita R, Silva Junior LC, Santana FM, de Oliveira T, Alcântara R, Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: Systematic review.Wien Klin Wochenschr.2021Apr; 133:(7–8):377–82.https://doi.org/10.1007/s00508-020-01760-4
     [Google Scholar]
  4. Soheili M, Khateri S, Moradpour F, Mohammadzedeh P, Zareie M, Mortazavi SMM, et al. The efficacy and effectiveness of COVID-19 vaccines around the world: A mini-review and meta-analysis.Ann Clin Microbiol Antimicrob.2023May 19; 22:(1):42.https://doi.org/10.1186/s12941-023-00594-y
     [Google Scholar]
  5. Kolahchi Z, De Domenico M, Uddin LQ, Cauda V, Grossmann I, Lacasa L, et al. COVID-19 and its global economic impact.Adv Exp Med Biol.2021 :1318::825–37.https://doi.org/10.1007/978-3-030-63761-3_46
     [Google Scholar]
  6. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.N Engl J Med.2021Feb 4; 384:(5):403–16. https://doi.org/10.1056/NEJMoa2035389
     [Google Scholar]
  7. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study.Lancet Infect Dis.2021Jul; 21:(7):939–49.https://doi.org/10.1016/S1473-3099(21)00224-3
     [Google Scholar]
  8. Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: An observational study of reports to the vaccine adverse event reporting system and v-safe.Lancet Infect Dis.2022Jun; 22:(6):802–12.https://doi.org/10.1016/S1473-3099(22)00054-8
     [Google Scholar]
  9. Klimek L, Bergmann KC, Brehler R, Pfützner W, Zuberbier T, Hartmann K, et al. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI. Allergo J Int. 2021 30:(3):79–95. https://doi.org/10.1007/s40629-021-00165-7
     [Google Scholar]
  10. Oh TH, Woo SH, Hong S, Lee C, Lee WJ, Jeong SK. Clinical features of patients presenting to the emergency department with cardiovascular adverse reactions after COVID-19 mRNA vaccination. J Korean Med Sci. 2022Mar 2; 37:(9):e73. https://doi.org/10.3346/jkms.2022.37.e73
     [Google Scholar]
  11. Kaur RJ, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, et al. Cardiovascular adverse events reported from COVID-19 vaccines: A study based on WHO database. Int J Gen Med. 2021Jul 27: 14::3909–27. https://doi.org/10.2147/IJGM.S324349
     [Google Scholar]
  12. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021 4:(12):e2140364. https://doi.org/10.1001/jamanetworkopen.2021.40364
     [Google Scholar]
  13. Perrotta A, Biondi-Zoccai G, Saade W, Miraldi F, Morelli A, Marullo AG, et al. A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med. 2021Sep; 63:(3):324–31. https://doi.org/10.23736/S0031-0808.21.04435-9
     [Google Scholar]
  14. Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE—an observational study. Front Public Health. 2022May 6:10:876336. https://doi.10.3389/fpubh.2022.876336
     [Google Scholar]
  15. Dhamanti I, Suwantika AA, Adlia A, Yamani LN, Yakub F. Adverse Reactions of COVID-19 vaccines: A scoping review of observational studies. Int J Gen Med. 2023Feb 20;16:609–18. https://doi.org/10.2147/IJGM.S400458
     [Google Scholar]
  16. Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). 2022[cited 2024 Jul 26]. Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html
     [Google Scholar]
  17. Mundodan JH, Hasnain S, Al Jubni H, Khogali H, Al Bayat S, Al-Romaihi H. Adverse events following immunization (AEFI) surveillance in Qatar: 2014–2018. J Pharmacovigil. 2020 8:(4):287. https://doi.org/10.35248/2329-6887.20.8.287
     [Google Scholar]
  18. Key Lessons from COVID-19: A narrative review describing Qatar’s multifactorial approach in executing a vaccination campaign. Vaccines (Basel). 2023May 6; 11:(5):953. https://doi.10.3390/vaccines11050953
     [Google Scholar]
  19. Abdeen S, Alah MA, Al-Zaidan M, Ibrahim MIM, Abdulmajeed J, Al-Nuaimi AA, et al. Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: A retrospective study. 2024Apr 10:12:1384327. https://doi.10.3389/fpubh.2024.1384327
     [Google Scholar]
  20. Aldali J, Meo SA, Al-Khlaiwi T. Adverse effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 vaccines among the adult population in Saudi Arabia: A cross-sectional study. Vaccines (Basel). 2023Jan 20; 11:(2):231. https://doi.org/10.3390/vaccines11020231
     [Google Scholar]
  21. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021Feb; 25:(3):1663–9. https://doi.org/10.26355/eurrev_202102_24877
     [Google Scholar]
  22. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring – United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021Feb 26; 70:(8):283–8. https://doi.org/10.15585/mmwr.mm7008e3
     [Google Scholar]
  23. Mediouni M, Madiouni R, Kaczor-Urbanowicz KE. COVID-19: How the quarantine could lead to the depreobesity. Obes Med. 2020Sep;19:100255. https://doi.org/10.1016/j.obmed.2020.100255
     [Google Scholar]
/content/journals/10.5339/qjph.2025.4
Loading
Adverse events of COVID-19 vaccines: Insights from primary health care centers in Qatar
QJPH 2025, 4 (2025); https://doi.org/10.5339/qjph.2025.4
/content/journals/10.5339/qjph.2025.4
/content/journals/10.5339/qjph.2025.4
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): adverse drug events, COVID-19, pharmacovigilance, primary care, safety surveillance and vaccine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error